Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001437749-23-035285
Filing Date
2023-12-26
Accepted
2023-12-22 19:54:53
Documents
5
Effectiveness Date
2023-12-26

Document Format Files

Seq Description Document Type Size
1 FORM S-8 navb20231222_s8.htm S-8 43593
2 EXHIBIT 5.1 ex_609875.htm EX-5.1 5494
3 EXHIBIT 23.2 ex_609877.htm EX-23.2 3079
4 EXHIBIT FILING FEES ex_609741.htm EX-FILING FEES 13821
5 maslon01.jpg GRAPHIC 3265
  Complete submission text file 0001437749-23-035285.txt   71765
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-276266 | Film No.: 231511152
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)